Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCT400 vs rituximab plus CHOP in first-line CD20-positive DLBCL
CTR20160368Phase 3Completed
- Sponsor
- Sinocelltech Group Limited
- Start
- Jun 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of ripertamab in diffuse large B-cell lymphoma (DLBCL), sponsored by Sinocelltech Group Limited. Started Jun 2016; status: completed.
02
Drugs
ripertamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on CTR20160368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20160368.